

Patient Perspectives on Use of a Water-based Calcipotriene and Betamethasone Dipropionate Cream Formulation for the Treatment of Plaque Psoriasis

Michael A. Vecchiolla, BS,¹ Neal Bhatia, MD²

¹EPI Health, LLC, Charleston, SC; ²Therapeutics Clinical Research, San Diego, CA

Synopsis

- Patient satisfaction with topical medications for the treatment of plaque psoriasis is directly related to adherence and real-world efficacy¹
- Poor cosmetic characteristics and the time-consuming nature of greasy topical agents cause up to 75% of patients to become nonadherent with topical psoriasis treatments^{2,3}
- Most patients have mild psoriasis that is amenable to topical therapies⁴
- WYNZORA[®] (calcipotriene [CAL] and betamethasone dipropionate [BDP] 0.005%/0.064%) cream is a novel, moisturizing, water-based cream formulation⁵
 - Polyaphron dispersion (PAD) technology allows formulation and efficient topical delivery of challenging molecules while maintaining a favorable aesthetic feel⁶
 - Suitable for psoriasis treatment on both body and scalp⁶

Objective

- To assess patient satisfaction with CAL/BDP cream applied once daily to affected areas

Methods

- Patient satisfaction data were collected using a 6-item survey about their experiences using the cream
 - Included in new patient prescription kits
 - Distributed by dermatology healthcare providers in November 2021
 - Completed 1 week after treatment initiation
- Patients responded using a 5-item Likert scale (strongly agree, agree, neutral, disagree, strongly disagree)
- Survey results are based on the pooled number of strongly agree, agree, and neutral responses to each survey statement

Results

- 113 adults with plaque psoriasis completed surveys

Baseline Characteristics

Figure 1: Psoriasis Severity




Figure 2: Psoriasis Treatment Duration



Figure 3: First Topical Prescription Medication for Psoriasis



Figure 4: Mean Duration of CAL/BDP Cream Use

10.4 days



^aOther therapies included topical steroids (n=46); generic calcipotriene/betamethasone (n=17); Enstilar[®] Foam (n=17); Duobrii[®] Lotion (n=15); topical steroids (n=46); Taclonex[®] (n=10); calcipotriene (alone) (n=9); Otezla[®] (n=5); infused biologics (n=3).

Patient Perspectives

- Patient experiences with CAL/BDP cream were positive

Figure 5: Patient Satisfaction Survey Results





Figure 6: Locations of CAL/BDP Cream Use



Conclusions

- Patients with plaque psoriasis strongly preferred a novel, water-based CAL/BDP cream formulation to previously used prescription topical therapies
- Most patients reported the CAL/BDP cream was well tolerated, moisturized plaques, and resulted in visible improvement within 1 week
- Rapid improvement may limit treatment discontinuation rates
- Tolerability of topical therapies is also particularly important as some surfactants cause skin irritation
- A key benefit of the PAD formulation used in WYNZORA cream is a reduced surfactant requirement compared to conventional emulsion systems

References

1. Carroll C, et al. *Br J Dermatol*. 2004;151(4):895-92.
2. Feldman SR, et al. *Dermatol Ther (Heidelb)*. 2021;11(6):2077-88.
3. Curcio A, et al. Improving patient acceptability and adherence in psoriasis treatment. Poster presented at the 42nd Annual Fall Clinical Dermatology Conference[®], October 20-23, 2022; Las Vegas, NV.
4. Armstrong AW, Read C. *JAMA*. 2020;323(19):1945-60.
5. Wynzora. Prescribing information. EPI Health; 2021.
6. Praestegaard M, et al. *Dermatol Ther (Heidelb)*. 2022;12(10):2217-31.

Funding Sources and Disclosures

The patient survey and poster development were funded by EPI Health, a Novan company. Dr. Bhatia is a scientific advisor to EPI Health, and Mr. Vecchiolla is an EPI Health employee.

NOVAN